

---

## Active Biotech Q3 2024 - Rights Issue Funds Laquinimod

Redeye comments on Active Biotech's Q3 report. During the quarter, Active Biotech reported laquinimod concentrations in the vitreous segment of the eye and a rights issue. The rights issue can fund the the company through the completion of the laquinimod's biodistribution study in 2025, which may position it for a licensing deal.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Active Biotech Q3 2024 - Rights Issue Funds Laquinimod](#)